Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M-M-R II (rHA) and VARIVAX IM vs SC Study
NCT00432523Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2005
- Primary completion
- Sep 2005
- Modality
- Live Attenuated Vaccines, DNA Vaccines, Live Biotherapeutic Products
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of M-M-R II and varicella virus vaccine live in measles, mumps, rubella and 1 more (2 arms), sponsored by Merck & Co. Primary endpoints: Antibody response rate to measles at 42 days, Antibody response rate to mumps at 42 days and 2 more. Started Jan 2005; status: completed.
02
Drugs
M-M-R IIvaricella virus vaccine live
03
Conditions
measlesmumpsrubellavaricella (VZV)
Beyond the preview
Go deeper on NCT00432523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00432523.